🇺🇸 FDA
Patent

US 10668055

Cancer treatment using combinations of ERK and RAF inhibitors

granted A61KA61K31/428A61K31/437

Quick answer

US patent 10668055 (Cancer treatment using combinations of ERK and RAF inhibitors) held by Biomed Valley Discoveries, Inc. expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Biomed Valley Discoveries, Inc.
Grant date
Tue Jun 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K31/428, A61K31/437, A61K31/44, A61K31/4439